Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology
Summary
Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.
Bill status
in committee
1 of 4 stages cleared
Introduction
Jan 2023
Committee Review
Floor Vote
Governor
Introduced Jan 4, 2023
Last action Jan 3, 2024
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
2
Jan 3, 2024
Assembly · Referred to committee
REFERRED TO INSURANCE
Jan 4, 2023
Assembly · Referred to committee
REFERRED TO INSURANCE
1 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Nader Sayegh
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about A 62
Scope: NY
Hi! I can help you understand A 62. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline